title: Keto acid-supplemented low-protein diet for treatment of adult patients with hepatitis B virus infection and chronic glomerulonephritis.
abstract: OBJECTIVE
  An open-label, randomized, controlled, single-centre clinical trial to evaluate the effects of low-protein intake, with or without keto acid supplementation, on nutritional status and proteinuria, in patients with hepatitis B virus (HBV) and early stage chronic glomerulonephritis.
  
  
  METHODS
  Patients with chronic glomerulonephritis and HBV infection were randomized to receive a low-protein diet (0.6-0.8 g/kg ideal body weight [IBW] per day) either without (LP group) or with (sLP group) keto acid supplementation (0.1 g/kg IBW per day), for 12 months. Nutritional, clinical and safety parameters were recorded.
  
  
  RESULTS
  The study included 17 patients (LP group n = 9; sLP group n = 8). Proteinuria and microalbuminuria were significantly lower in the sLP group at 6 and 12 months compared with baseline, and at 12 months compared with the LP group. There were no significant differences in serum creatinine level or estimated glomerular filtration rate. Nutritional parameters (serum albumin and prealbumin) were significantly improved at 12 months, compared with baseline, in the sLP group.
  
  
  CONCLUSIONS
  Restriction of dietary protein intake to 0.6-0.8 g/kg IBW per day appears to have an acceptable safety profile. Supplementation with keto acids is associated with decreased urine protein excretion.
authors.affiliation: Renal Division, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Mou
authors.forename: Jialin
authors.initials: J
authors.lastname: Li
authors.forename: Zanzhe
authors.initials: Z
authors.lastname: Yu
authors.forename: Qin
authors.initials: Q
authors.lastname: Wang
authors.forename: Zhaohui
authors.initials: Z
authors.lastname: Ni
mesh_terms: D000328:Adult; D002908:Chronic Disease; D003710:Demography; D018753:Diet, Protein-Restricted / Q000009:adverse effects; D019587:Dietary Supplements; D005260:Female; D005921:Glomerulonephritis / Q000150:complications* / Q000178:diet therapy* / Q000821:virology; D006509:Hepatitis B / Q000150:complications* / Q000178:diet therapy* / Q000821:virology; D006515:Hepatitis B virus / Q000502:physiology; D006801:Humans; D007651:Keto Acids / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
chemical_list: D007651:Keto Acids